JACC:延迟的支架置入能改善STEMI患者的预后?

2017-06-10 MedSci MedSci原创

既往,有研究表明心肌梗塞患者的支架置入推迟后,冠脉的血流和心肌的恢复会有所提高。然而,ST段抬高型心肌梗死患者最佳急性治疗方案的第三次DANish研究(Third DANish Study of Optimal Acute Treatment of Patients With ST-elevation Myocardial Infarction,DANAMI-3–DEFER)结果表明,对于ST段抬

既往,有研究表明心肌梗塞患者的支架置入推迟后,冠脉的血流和心肌的恢复会有所提高。然而,ST段抬高型心肌梗死患者最佳急性治疗方案的第三次DANish研究(Third DANish Study of Optimal Acute Treatment of Patients With ST-elevation Myocardial InfarctionDANAMI-3–DEFER)结果表明,对于ST段抬高型心梗(STEMI)患者,及时的经皮冠状动脉介入治疗(PCI)和延迟的支架置入治疗效果没有显著差异。

本研究旨在评估延迟的支架置入治疗对STEMI患者在梗塞面积、心肌抢救和微血管阻塞(MVO)方面的影响。在DANAMI-3亚组研究中,510STEMI患者被随机分组至PCI伴及时的支架置入组和PCI伴延迟的支架置入组,所以患者出院前和3个月后都会接受心脏磁共振检查,主要终点事件就是心肌梗塞面积。

结果表明,延迟的支架置入没有减少最终的梗塞面积(9%左室;四分位数:3%-18% vs 10%左室;p=0.67)。相似地,延迟的支架置入与心肌抢救(66%;四分位数:50%-89% vs 67%p=0.80)和微血管阻塞(43% vs 42%; p = 0.78)均不相关。进一步分析发现,在7个亚组中,支架长度是唯一影响预后的因素,当支架长度≥24mm时,延迟的支架置入能减少心肌的梗塞面积((6% 左室; 四分位数: 2% to 18% vs 13% 左室; p = 0.006)。

常规的延迟支架置入不会减少心梗面积或MVO,并且这些研究结果不支持延迟的支架置入治疗方案运用在经PCI治疗后的STEMI患者中。

原始出处:

Jacob.L et al.Myocardial Damage in Patients With Deferred Stenting After STEMI:A DANAMI-3–DEFER Substudy.JACC.2017 June.  Doi:10.1016/j.jacc.2017.03.601

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853648, encodeId=5c341853648b5, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jul 25 11:00:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936705, encodeId=0e4b1936e0541, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Mon Dec 04 21:00:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325388, encodeId=1b4213253883f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jun 12 06:00:00 CST 2017, time=2017-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481990, encodeId=b3bb1481990b5, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Mon Jun 12 06:00:00 CST 2017, time=2017-06-12, status=1, ipAttribution=)]
    2017-07-25 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853648, encodeId=5c341853648b5, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jul 25 11:00:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936705, encodeId=0e4b1936e0541, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Mon Dec 04 21:00:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325388, encodeId=1b4213253883f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jun 12 06:00:00 CST 2017, time=2017-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481990, encodeId=b3bb1481990b5, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Mon Jun 12 06:00:00 CST 2017, time=2017-06-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853648, encodeId=5c341853648b5, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jul 25 11:00:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936705, encodeId=0e4b1936e0541, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Mon Dec 04 21:00:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325388, encodeId=1b4213253883f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jun 12 06:00:00 CST 2017, time=2017-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481990, encodeId=b3bb1481990b5, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Mon Jun 12 06:00:00 CST 2017, time=2017-06-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853648, encodeId=5c341853648b5, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jul 25 11:00:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936705, encodeId=0e4b1936e0541, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Mon Dec 04 21:00:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325388, encodeId=1b4213253883f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jun 12 06:00:00 CST 2017, time=2017-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481990, encodeId=b3bb1481990b5, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Mon Jun 12 06:00:00 CST 2017, time=2017-06-12, status=1, ipAttribution=)]

相关资讯

HEART:中国学者证实ERP与动脉粥样硬化危险因素的长期预后相关性

既往研究表明早期复极化模式(ERP)在无结构性心脏病患者中与突发心源性死亡(SCD)相关。然而,尚未有研究证实ERP在动脉粥样硬化性心脏病高危人群中的预后价值。

郎平呼吁关注糖尿病心血管并发症,糖尿病管理需“五驾马车”

数据显示,中国糖尿病患者已经跃居世界首位,患病率已达11.6%,更为可怕的是,50.1%的中国人正处于糖尿病前期。需要重视的是,中国Ⅱ型糖尿病患病人群中80%合并心血管危险因素,血糖达标率低,血糖/血脂/血压综合达标率更低,且还未得到重视,治疗率只占25.8%。中国女排总教练郎平的父亲也是一位糖尿病患者,像很多患者一样,血糖高、血压高、体重也高,是名副其实的“三高”。而在父亲患病和治疗过程中,无论

Circulation:PAI-1调控心肌细胞TGF-β信号及心脏纤维化

纤维化是压力性组织重塑和基质增生的病理结果。高水平纤溶酶原激活物抑制剂I型(PAI-1)已在多器官系统被证实与纤维化相关。然而,与此矛盾的是,在小鼠研究中,PAI-1的基因纯合缺陷会引起自发性年龄依赖性心脏选择性纤维化。本研究揭示了PAI-1在心肌受损后调控心肌纤维化和心脏转录因子的信号网络的新机制。

Circulation:TAVR术前后运动量的变化与临床预后的相关性研究

经皮主动脉瓣置换术(TAVR)是治疗主动脉瓣疾病最有效的方案之一。近日,在国际心血管权威杂志《Circulation》上发表了一篇关于探索TAVR术后不同的运动量对预后影响的临床研究。

JAHA:患有糖尿病的血液透析患者血糖控制与心血管结局之间的关系!

由此可见,HbA1c水平升高与糖尿病患者较高的心血管死亡率和心肌梗死发生率相关,但与卒中、外周动脉疾病或全因死亡率无显著相关性。

Circulation:多学科讨论——SPRINT研究颠覆认知 血压高低或有新标准?

SPRINT(收缩压干预试验)证实,美国处于较高的心血管疾病风险但不合并糖尿病、卒中或心衰的成人中,与收缩压(SBP)目标<140mmHg相比,<120mmHg可使全因死亡率降低27%。2017年4月,发表在《Circulation.》的一项研究量化了如美国采用SPRINT的强化血压方案的潜在获益和风险。